# A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors

> **NCT05193721** · PHASE1 · UNKNOWN · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 25 (actual)

## Conditions studied

- Advanced Malignant Tumors

## Interventions

- **DRUG:** SHR-1901

## Key facts

- **NCT ID:** NCT05193721
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-10
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-08-31
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05193721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05193721, "A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05193721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*